Novartis Oncology Strategy: Focus On The Microenvironment
As ASCO approaches, Novartis tries to highlight its oncology offerings, despite a very early immuno-oncology pipeline.
You may also be interested in...
The oncology player missed out on the first round of immune checkpoint inhibition and now some investors are wondering if the pharma needs to buy a rival to catch up. During the company’s second quarter sales call CEO Jimenez insisted Novartis has the internal expertise to execute.
Novartis AG's novel anticancer midostaurin is looking promising in the rare indication of advanced systemic mastocytosis given positive data from a pivotal Phase II study just published in the New England Journal of Medicine.
Monrovia, California-based Xencor Inc.'s latest collaboration, which is worth $150m up front and up to $2.41bn in milestone fees from Novartis AG, shows how the company is growing up as its research and development pipeline matures.